Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche Introduces New GS FLX+ Software

Published: Thursday, November 08, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
First high-throughput sequencing platform to deliver one million reads with read lengths of up to 1000 bp and beyond.

Roche has announced the launch and immediate availability of a new software package (v2.8) that significantly improves long-read shotgun sequencing performance on its GS FLX+ System.

This system is the first high-throughput sequencing platform to deliver one million reads with accuracy and length that are comparable to traditional Sanger-based methods.

The improvements will allow researchers to discover more novel complex genetic variants and uncover the hidden biology in difficult-to-sequence regions of genomes, transcriptomes, and metagenomic samples.

The GS FLX+ System and software will be presented at the American Society for Human Genetics Annual Meeting in San Francisco.

“This latest software release represents a major step forward in meeting the expectations of our customers on the long-read performance of the GS FLX+ System,” said Thomas Schinecker, President Roche Sequencing Solutions.

Schinecker continued, “Over 30 leading sequencing laboratories around the world are already implementing the latest improvements of our new software, and their feedback has been overwhelmingly positive.”

Since the launch of the GS FLX+ System, researchers have confirmed the value of extra-long reads for more complete de novo assembly of whole genomes, superior full-length transcriptome analysis, and better characterization of mixed metagenomic samples.

The latest software will further improve the sequencing results for these applications and also bring new functionality enhancements to the suite of 454 Sequencing System’s bioinformatics tools for de novo assembly, mapping, and variant analysis.

“We have experienced excellent results in our laboratory using the latest GS FLX+ software. All sequencing metrics, including read length, have exceeded our expectations,” explained Hiroshi Tarui, RIKEN Omics Science Center and Yokohama City University KIHARA Institute for Biological Research.

Tarui continued, “We are excited to use the platform in our de novo transcriptome studies, where the long reads are critical for full-length assembly of cDNA transcripts and splice variant investigation.”

“We have been using the GS FLX+ System extensively for our de novo sequencing project of different tobacco strains achieving modal read lengths of around 820 bases and several runs with an output of more than 1 Gb,” said Bernd Timmermann, Head of the Max Planck Institute Sequencing Core Facility, Berlin, Germany.

Timmermann continued, “With the upgrade to the v2.8 software, we are seeing an improvement in average and modal read length in all cases. We will continue to use our GS FLX+ Systems in the future for our de novo sequencing and metagenome projects.”

Roche also plans to roll out long-read improvements for long amplicon sequencing on the GS FLX+ System. They will advance sequencing results for targeted sequencing and 16S/18S rRNA metagenomic applications.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche to Acquire Kapa Biosystems
Acquisition to strengthen next-generation sequencing product offerings.
Friday, August 21, 2015
Roche's Investigational Immunotherapy Atezolizumab Shrank Tumours in People with Lung Cancer
Roche will discuss results with the U.S. FDA as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer.
Wednesday, August 19, 2015
Pivotal Phase II Study of Venetoclax Met Primary Endpoint
Venetoclax is a small molecule inhibitor of the BCL-2 protein, which potentially represents a new way of treating blood cancers.
Friday, August 14, 2015
Roche Acquires GeneWEAVE to Strengthen Offerings in Microbiology Diagnostics
GeneWEAVE’s Smarticles technology enhances Roche’s role in fighting drug-resistant bacteria.
Friday, August 14, 2015
Roche's Investigational Immunotherapy Shrank Bladder Cancer Tumors in Pivotal Study
The company have announced the success of atezolizumab in shrinking tumors people with locally advanced or metastatic urothelial bladder cancer.
Tuesday, July 14, 2015
Roche Acquires Ariosa Diagnostics
Acquisition will see Roche enter the non-invasive prenatal test (NIPT) and cell-free DNA testing services markets.
Wednesday, December 03, 2014
Roche Receives FDA Clearance for Strep A Test
The cobas Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection.
Friday, November 14, 2014
Roche to Invest in New Diagnostic Manufacturing Facility in China
The facility will address Asia Pacific’s growing demand for diagnostics.
Monday, November 10, 2014
Roche Invests For The Future In Its Basel Site
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development.
Thursday, October 23, 2014
Roche Acquires AbVitro Technology
Roche acquires rights to technology and patent applications from AbVitro to support next-generation sequencing pipeline.
Thursday, October 09, 2014
Roche and InterMune Reach Definitive Merger Agreement
Roche to acquire InterMune for US$ 74.00 per share.
Thursday, August 28, 2014
Roche, Garvan Institute Epigenomic Partnership
Roche and the Garvan Institute of Medical Research today announce a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.
Wednesday, August 20, 2014
FDA Approves Roche’s Advanced Cervical Cancer Chemotherapy
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.
Monday, August 18, 2014
Roche to Acquire Santaris Pharma
Acquisition to expand Roche's discovery and development of RNA-targeting medicines.
Tuesday, August 05, 2014
Roche to Acquire Seragon Pharmaceuticals
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer.
Wednesday, July 02, 2014
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!